Mural Oncology (MURA) Revenue & Revenue Breakdown
Mural Oncology Revenue Highlights
00
Mural Oncology Revenue by Period
Mural Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | - |
Mural Oncology generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Mural Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $3.49M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.62M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | - |
Mural Oncology generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Mural Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAP | Adaptimmune Therapeutics | $178.03M | $7.29M |
| VRCA | Verrica Pharmaceuticals | $7.57M | $12.70M |
| XFOR | X4 Pharmaceuticals | $2.56M | $28.81M |
| PLUR | Pluri | $1.34M | $185.00K |
| EYEN | Eyenovia | $57.34K | $14.72K |
| ANTX | AN2 Therapeutics | - | - |
| ITRM | Iterum Therapeutics | - | - |
| NCNA | NuCana | - | - |
| MURA | Mural Oncology | - | - |
| RANI | Rani Therapeutics | - | - |
| JSPR | Jasper Therapeutics | - | - |